Cypress Point Wealth Management, LLC - BROOKLYN IMMUNOTHERAPEUTICS ownership

BROOKLYN IMMUNOTHERAPEUTICS's ticker is BTX and the CUSIP is 114082100. A total of 39 filers reported holding BROOKLYN IMMUNOTHERAPEUTICS in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
Cypress Point Wealth Management, LLC ownership history of BROOKLYN IMMUNOTHERAPEUTICS
ValueSharesWeighting
Q2 2022$977,000
-74.7%
1,887,5090.0%1.71%
-56.4%
Q1 2022$3,869,000
-50.8%
1,887,5090.0%3.93%
-46.1%
Q4 2021$7,871,000
-10.3%
1,887,509
+100.0%
7.30%
+133.0%
Q3 2021$8,776,000
+3.3%
943,756
+100.0%
3.13%
-48.2%
Q2 2021$8,499,000471,8786.04%
Other shareholders
BROOKLYN IMMUNOTHERAPEUTICS shareholders Q3 2022
NameSharesValueWeighting ↓
Cypress Point Wealth Management, LLC 471,878$8,499,0006.04%
BALDWIN BROTHERS LLC/MA 44,116$795,0000.09%
DOWLING & YAHNKE LLC 15,806$285,0000.02%
INVERNESS COUNSEL LLC /NY/ 13,307$240,0000.01%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 15,000$270,0000.01%
Cutler Group LLC / CA 4,200$75,0000.00%
MetLife Investment Management, LLC 10,805$194,5980.00%
HAP Trading, LLC 13,900$64,0000.00%
METROPOLITAN LIFE INSURANCE CO/NY 8,272$148,9790.00%
Ameritas Investment Partners, Inc. 1,867$34,0000.00%
View complete list of BROOKLYN IMMUNOTHERAPEUTICS shareholders